AML was diagnosed with nucleophosmin-1 (NPM1) mutations and dual activating mutations in FMS-like tyrosine kinase 3 (FLT3-ITD and FLT3-TKD). This evidence concerns the gene FLT3 and acute myeloid leukemia.